Latus Bio Expands AI/ML Strategy with Two Renowned Scientific Advisors

Latus Bio, Inc., a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, has announced a significant expansion of its artificial intelligence and machine learning (AI/ML) strategy, marking a major breakthrough in its mission to revolutionize gene therapy delivery. The company has appointed two world-class scientific advisors, Pranam Chatterjee, PhD, and Philip M. Kim, PhD, to lead its AI/ML initiative.

The addition of Dr. Chatterjee and Dr. Kim positions Latus Bio at the forefront of AI-driven innovation in AAV capsid discovery and payload design. The company will leverage its unmatched capsid performance database, comprising data from nine extensive in vivo campaigns in non-human primates, covering 100 million plus unique "delivery zip codes" (route-capsid-tissue-cell type), to train predictive models that promise to accelerate capsid and payload discovery with unprecedented precision. Unlike traditional AI/ML-first approaches, Latus begins with an expansive in vivo dataset, deploying multi-dimensional information to enable predictive models that optimize cellular and tissue-level activity across the human body.

Key Takeaways:

• Latus Bio has appointed two world-class scientific advisors, Pranam Chatterjee, PhD, and Philip M. Kim, PhD, to lead its AI/ML initiative.
• The company's AI/ML strategy aims to accelerate AAV capsid and payload discovery with unprecedented precision, leveraging its unmatched capsid performance database.
• Latus' AI/ML initiative will focus on three core areas: AAV capsid engineering, payload engineering, and bespoke therapeutic tailoring.
• The company's AI/ML models are expected to more efficiently prioritize capsid-tissue pairings, guide payload design, and uncover hidden sequence-function relationships.
• Latus' strategic evolution positions the company at the forefront of AI-driven innovation in AAV gene therapy.
• The addition of Dr. Chatterjee and Dr. Kim brings unique expertise in protein modeling and machine learning, setting Latus up for significant advancements in gene therapy delivery.

Statistics:

• Latus' AI/ML initiative will leverage data from nine extensive in vivo campaigns in non-human primates, covering 100 million plus unique "delivery zip codes."
• The company's capsid performance database comprises data from multiple in vivo studies, providing a robust foundation for its AI/ML models.
• The goal of Latus' AI/ML strategy is to accelerate capsid and payload discovery, promising to unlock new delivery tropisms beyond traditional tissues like liver, muscle, and eye.

Sources:

• https://www.businesswire.com/news/home/20251103349850/en/
• www.latusbio.com